Humana Company Profile (NYSE:HUM)

Humana trades on the New York Stock Exchange (NYSE) under the ticker symbol "HUM."

Humana announced a quarterly dividend on Thursday, April 20th. Stockholders of record on Friday, June 30th will be given a dividend of $0.40 per share on Monday, July 31st. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.69%. The ex-dividend date of this dividend is Wednesday, June 28th. View Humana's Dividend History.

Humana declared that its Board of Directors has approved a stock repurchase plan on Tuesday, April 11th 2017, which permits the company to buyback $2,250,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 7.3% of its stock through open market purchases. Stock buyback plans are typically a sign that the company's board of directors believes its stock is undervalued.

Humana Inc (NYSE:HUM) issued its quarterly earnings data on Wednesday, May, 3rd. The company reported $2.75 EPS for the quarter, topping analysts' consensus estimates of $2.55 by $0.20. The business had revenue of $13.76 billion for the quarter, compared to analyst estimates of $13.61 billion. Humana had a return on equity of 13.09% and a net margin of 1.09%. During the same period last year, the business earned $1.86 EPS. View Humana's Earnings History.

Humana is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Humana.

Humana updated its FY17 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share guidance of $11.10+ for the period, compared to the Thomson Reuters consensus estimate of $11.15.

18 brokers have issued twelve-month price targets for Humana's shares. Their forecasts range from $170.00 to $240.00. On average, they anticipate Humana's share price to reach $212.73 in the next year. View Analyst Ratings for Humana.

Here are some recent quotes from research analysts about Humana stock:

• 1. According to Zacks Investment Research, "Humana’s continuous margin growth, accretive acquisitions, efficient capital deployment, business diversification initiatives and consistent revenue growth paved the way for long-term growth. The company’s earnings per share of $2.75 beat the Zacks Consensus Estimate and improved 38% year over year, primarily due to the receipt of the break up fee from the terminated merger with Aetna and outstanding performance by the Retail segment. Its strong balance sheet is another positive. In fact, the stock gained 32% as against the Zacks categorized HMO industry’s increase of 30%, in last one year. However, cancellation of the merger with Aetna, which would have solidified its position in the industry, lowered Humana’s face value in the market. Moreover, stiff competition, and weakness in individual commercial business raise concerns." (5/25/2017)
• 2. Cantor Fitzgerald analysts commented, "We are transferring coverage of Humana (HUM) and rate the shares at Neutral; our 12-month DCF-based price target is $186. The shares trade 6% above our price target, probably due in part to continued speculation that HUM remains a takeover candidate. We believe there is a low probability that AET will successfully appeal a recent court decision which ruled against the merger (if it even decides to appeal the decision). We assign a low probability that HUM will be acquired, at least in the short term. HUM's losses relating to the Affordable Care Act will shrink in 2017 and 2018. Medicare continues to perform well, recognizing that HUM 2018 MA reimbursement could be impacted by a reduction in its star ratings. With about 6% downside to our target price, our rating is Neutral." (2/6/2017)

Some companies that are related to Humana include Anthem (ANTM), Aetna (AET), CIGNA (CI), Express Scripts Holding Company (ESRX), Centene Corp (CNC), WellCare Health Plans (WCG), Health Net (HNT), Molina Healthcare (MOH), Magellan Health (MGLN), Health Insurance Innovations (HIIQ), Connecture (CNXR) and Universal American (UAM).

Humana's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include CAPITAL WORLD INVESTORS (10.10%), BlackRock Inc. (8.30%), Vanguard Group Inc. (6.52%), State Street Corp (4.35%), Glenview Capital Management LLC (3.68%) and FMR LLC (3.38%). Company insiders that own Humana stock include Brian P Leclaire, Bruce D Broussard, Cynthia H Zipperle, David A Jr/Ky Jones, James E Murray, Jody L Bilney, M Todoroff Christopher, Roy A Beveridge and Timothy S Huval. View Institutional Ownership Trends for Humana.

Humana's stock was sold by a variety of institutional investors in the last quarter, including Glenview Capital Management LLC, Marshall Wace LLP, OppenheimerFunds Inc., Morgan Stanley, State of New Jersey Common Pension Fund D, Public Employees Retirement Association of Colorado, OZ Management LP and ING Groep NV. Company insiders that have sold Humana stock in the last year include Brian P Leclaire, Bruce D Broussard, Cynthia H Zipperle, David A Jr/Ky Jones, James E Murray, Jody L Bilney, M Todoroff Christopher, Roy A Beveridge and Timothy S Huval. View Insider Buying and Selling for Humana.

Humana's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, Renaissance Technologies LLC, Wellington Management Group LLP, AQR Capital Management LLC, MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P. and Sachem Head Capital Management LP. View Insider Buying and Selling for Humana.

Shares of Humana can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Humana stock can currently be purchased for approximately $232.25.